The NuVasive (NUVA) Earns Daily News Impact Rating of 0.14

The NuVasive (NUVA) Earns Daily News Impact Rating of 0.14

These are some of the news headlines that may have impacted Alpha One’s scoring:

News headlines about NuVasive (NASDAQ:NUVA) have been trending somewhat positive this week, AlphaOne Sentiment reports. The research firm, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuVasive earned a news sentiment score of 0.14 on AlphaOne’s scale. AlphaOne also gave press coverage about the medical device company an impact score of 56 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the stock’s share price in the next few days.

Shares of NuVasive (NASDAQ:NUVA) opened at 77.65 on Monday. The stock has a 50 day moving average price of $73.43 and a 200-day moving average price of $71.16. The firm has a market cap of $3.93 billion, a PE ratio of 81.48 and a beta of 0.86. NuVasive has a 52-week low of $56.65 and a 52-week high of $77.88. NuVasive (NASDAQ:NUVA) last released its earnings results on Tuesday, April 25th. The medical device company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.01. The company had revenue of $249.86 million during the quarter, compared to the consensus estimate of $250.52 million. NuVasive had a net margin of 3.29% and a return on equity of 12.26%. The company’s revenue was up 16.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.34 EPS. On average, equities analysts anticipate that NuVasive will post $2.01 EPS for the current fiscal year.

In related news, insider Jason Hannon sold 24,840 shares of the business’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $74.22, for a total transaction of $1,843,624.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.70% of the stock is owned by corporate insiders. NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NUVA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment